CD274 and lung carcinoma: These results are underlined in the clinical setting by the KEYNOTE-024 study in lung cancer showing therapeutic superiority of pembrolizumab over platinum-based chemotherapy with increased PFS and OS in patients with a high PD-L1 tumor proportion score ≥50% [42].